



Myrexis to Present at 10th Annual JMP Securities Research Conference

SALT LAKE CITY, May 3, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced that Adrian Hobden, Ph.D., President and Chief Executive Officer, is scheduled to present an overview of the Company at the 10th Annual JMP Securities Research Conference to be held May 9 — 11, 2011 in San Francisco, CA.

Dr. Hobden and Robert Lollini, Chief Financial Officer and Treasurer, will be available to participate in one-on-one meetings with investors attending the conference.

Event: 10th Annual JMP Securities Research Conference

Date: Wednesday, May 11, 2011

Time: 8:30 am (PDT)

Place: The Ritz-Carlton, San Francisco

The presentation will be audio webcast live and can be accessed by visiting the investor relations section of the Myrexis website at www.myrexis.com. The webcast will be archived for 90 days.

About Myrexis, Inc.

Myrexis, Inc. is a biotechnology company focused on developing and commercializing novel treatments for cancer. The Company has leveraged a unique understanding of the genetic causes of human disease to generate a strong pipeline of clinical and preclinical product candidates. These include compounds with distinct mechanisms of action and novel chemical structures that have first-in-class and/or best-in-class therapeutic potential. Myrexis is led by an experienced management team with expertise in all aspects of pre-clinical, clinical and commercial drug development.

The Company's oncology pipeline is led by [Azixa®](#) (verubulin, MPC-6827), a novel small molecule microtubule destabilizing agent in Phase 2 clinical development for the treatment of brain cancers. Additional novel, potent, small molecule oncology compounds include [MPC-3100](#), a fully-synthetic inhibitor of Hsp90 in Phase 1; and [MPC-9528](#), a Cancer Metabolism Inhibitor (CMI) in IND-enabling studies. Myrexis is also evaluating [MPI-0485520](#), an orally bioavailable, potent and selective small molecule inhibitor of type I interferon production that is being developed for the treatment of autoimmune diseases.

For more information, please visit www.myrexis.com.

The Myrexis, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=6327>

Azixa, Myrexis and the Myrexis logo are trademarks or registered trademarks of Myrexis, Inc. in the United States and foreign countries.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes, expected development, and potential efficacy of Myrexis' product candidates. These "forward-looking statements" and information included in the Company overview to be presented at the 10th Annual JMP Securities Research Conference are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied therein. These risks and uncertainties include, but are not limited to the factors discussed under the heading "Risk Factors" contained in Myrexis' Form 10-K, for the year ended June 30, 2010, which was filed with the Securities and Exchange Commission on September 13, 2010, as well as any updates to those risk factors filed from time to time in Myrexis' Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myrexis undertakes no duty to update this information unless required by law.

CONTACT: Myrexis, Inc.

Wayne Laslie

Chief Operating Officer

801-214-7822

investor.relations@myrexix.com

The Ruth Group

Stephanie Carrington (investors)

(646) 536-7017

scarrington@theruthgroup.com

Jason Rando (media)

(646) 536-7025

jrando@theruthgroup.com